Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Kronos Bio

Kronos Bio
2017 FOUNDED
PRIVATE STATUS
Series A LATEST DEAL TYPE
$105M LATEST DEAL AMOUNT
12 INVESTORS
Description

Developer of therapies that modulate historically undruggable targets. The company leverage deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Primary Office
  • 1300 South El Camino Real
  • Suite 300
  • San Mateo, CA 94402
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Kronos Bio’s full profile, request a free trial.

Kronos Bio Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 13-Jul-2019 $105M 00000 00000 Completed Startup
2. Seed Round 23-May-2018 0000 0000 0000 Completed Pre-Clinical Trials
1. Platform Creation 01-Jan-2017 Completed Pre-Clinical Trials
To view this company’s complete deal history including valuation and funding, request access »

Kronos Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00.00 00.00 00 00.00 00.00
Seed 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view this company’s complete Cap Table, request access »

Kronos Bio Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
GV Corporate Venture Capital Minority 000 0000 000000 0
Nextech Invest Venture Capital Minority 000 0000 000000 0
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
Polaris Partners Venture Capital Minority 000 0000 000000 0
The Invus Group PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Kronos Bio Executive Team (5)

Name Title Board
Seat
Contact
Info
Norbert Bischofberger Ph.D Chief Executive Officer, President & Board Member
Christopher Wilfong Chief Operating Officer & Co-Founder
Philip Gutry Chief Business Officer
Jorge Dimartino Ph.D Chief Medical Officer & Executive Vice President
Angela Koehler Ph.D Scientific Founder

Kronos Bio Board Members (8)

Name Representing Role Since Contact
Info
Arie Belldegrun MD Vida Ventures (Boston) Chairman 000 0000
David Tanen Two River Group Board Member 000 0000
Jakob Loven Ph.D Nextech Invest Board Member 000 0000
John Martin Ph.D Self Board Member 000 0000
Joshua Kazam Two River Group Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »